Introduction {#section1-0269881120907991}
============

Serotonin is critically involved in processing aversive outcomes ([@bibr1-0269881120907991]; [@bibr2-0269881120907991]; [@bibr8-0269881120907991]; [@bibr9-0269881120907991]) and adapting behaviour as circumstances change ([@bibr7-0269881120907991]; [@bibr8-0269881120907991]). Probabilistic reversal learning (PRL) paradigms model both: individuals learn by trial and error the most adaptive action in an acquisition stage, and this rule changes in a reversal phase ([@bibr2-0269881120907991]; [@bibr3-0269881120907991]; [@bibr4-0269881120907991]; [@bibr6-0269881120907991]; [@bibr8-0269881120907991]; [@bibr9-0269881120907991]). Severe serotonin depletion via neurotoxins impairs the ability to update actions upon reversal and increases sensitivity to negative feedback (SNF) in rats ([@bibr1-0269881120907991]) and monkeys ([@bibr8-0269881120907991]). SNF is defined here as switching behaviour following spurious negative feedback ('lose--shift'), which should be ignored; increased SNF thus causes subjects to choose the less rewarded stimulus, maladaptively. SNF is additionally elevated following single dose administration of selective serotonin reuptake inhibitors (SSRIs) in rats ([@bibr1-0269881120907991]) and healthy humans ([@bibr2-0269881120907991]; [@bibr9-0269881120907991]). These SSRI data are interpreted as the paradoxical lowering of serotonin ([@bibr1-0269881120907991]; [@bibr2-0269881120907991]; [@bibr9-0269881120907991]), presumed to parallel the effects following acute tryptophan depletion (ATD), which lowers serotonin synthesis ([@bibr4-0269881120907991]; [@bibr5-0269881120907991]; [@bibr6-0269881120907991]). Whilst studies of healthy humans have not found effects of ATD on choice in PRL, their samples have been small and studied only one sex: [@bibr4-0269881120907991] included 12 males whereas [@bibr6-0269881120907991] enrolled 12 females. Here we studied a large sample of healthy volunteers, male and female, to better determine whether ATD modulates choice behaviour in PRL. Whereas [@bibr4-0269881120907991] and [@bibr6-0269881120907991] used within-subjects designs, here we employed a between-subjects design to avoid practice effects and thus better assess learning.

Methods {#section2-0269881120907991}
=======

Power calculation was performed, with α = .05 (two-tailed), power (1-β) set to .8, and mean and standard deviation based on statistically significant PRL results from [@bibr9-0269881120907991]. This called for a group size of approximately *n* = 30. We studied 62 healthy volunteers, free from personal or immediate family psychiatric history. Participants were free from neurological, gastrointestinal or other major medical disorders, and were not taking any medication, besides contraceptives, nor had they taken psychiatric or neurological medication in the past. Volunteers gave informed consent and were paid.

Participants fasted for at least 9 h before the study, then gave a baseline blood sample, and ingested either a tryptophan depletion mixture (*n* = 30; 14 females) or a placebo mixture, containing tryptophan (*n* = 32; 15 females). The depletion mixture contained 4.10 g L-alanine, 3.70 g L-arginine, 8.93 g L-aspartic acid, 2.00 g L-cystine, 2.40 g glycine, 2.40 g L-histidine, 6.00 g L-isoleucine, 10.10 g L-leucine, 6.70 g L-lysine, 2.30 g L-methionine, 4.30 g L-phenylalanine, 9.20 g L-proline, 5.20 g L-serine, 4.90 g L-threonine, 3.00 g L-tyrosine, 6.70 g L-valine. The placebo mixture was identical but contained 5.20 g of L-tryptophan. These quantities were derived from [@bibr11-0269881120907991] and the mixtures were manufactured by metaX Institut fur Diatetik GmbH. After approximately 4.5 h, participants gave a second blood sample to verify depletion, and completed the PRL task. The task ([@bibr2-0269881120907991]; [@bibr6-0269881120907991]; [@bibr9-0269881120907991]) contained 80 trials: 40 during acquisition and 40 following reversal. For the first 40 trials, one option yielded positive feedback on 80% of trials, the other option on 20% of trials. These contingencies reversed for the latter 40 trials. Eight consecutive correct responses fulfilled the learning criterion.

SNF was our primary outcome measure, defined as the observed probability of behaviour switching away from the correct stimulus, following the delivery of spurious negative feedback. We likewise conducted planned comparisons on proportions for win--stay and lose--shift separately for spurious and veracious feedback, and for each phase ([@bibr9-0269881120907991]) reported in [Table 1](#table1-0269881120907991){ref-type="table"}. We calculated two measures of perseveration: immediately following reversal ([@bibr6-0269881120907991]) and across the reversal phase ([@bibr3-0269881120907991]).

###### 

Top: Summary of measures of choice behaviour, planned contrasts assessed by *t*-test. Bottom: Blood results.
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  Phase         Measure                    Feedback    Placebo           Depletion         *p*                    Cohen's *d*
  ------------- -------------------------- ----------- ----------------- ----------------- ---------------------- -------------
  Acquisition   Correct responses                      38.63 (3.2)       39.27 (1.82)      .34                    .25
                Trials to criterion                    10.59 (6.76)      9.83 (4.63)       .61                    .13
                Win--stay                  Veracious   .97 (.07)         .98 (.04)         .326                   .18
                Lose--shift                Spurious    .06 (.16)         .03 (.1)          .478                   .22
  Reversal      Correct responses                      33.44 (4.7)       34.13 (4.06)      .536                   .16
                Trials to criterion                    16.63 (8.57)      15.23 (7.6)       .502                   .17
                Win--Stay                  Veracious   .93 (.13)         .96 (.1)          .331                   .26
                Lose--Shift                Spurious    .11 (.19)         .12 (.17)         .889                   .06
                Perseveration, immediate               3.69 (2.1)        3.97 (2.0)        .594                   .137
                Perseveration, phase                   3.81 (3.68)       3.67 (3.0)        .865                   .042
  Blood         TRP:LNAA (1)                           .11 (.02)         .10 (.02)         .239                   .50
                TRP:LNAA (2)                           .11 (.03)         .005 (.004)       **4.96 × 10** ^--20^   4.9
                Valine (1)                             225 (45.10)       230 (46.56)       .662                   .11
                Valine (2)                             841.30 (238.69)   820.86 (218.96)   .733                   .09
                Methionine (1)                         29.60 (4.98)      27.62 (6.44)      .191                   .34
                Methionine (2)                         67.70 (23.97)     63.07 (20.71)     .431                   .21
                Isoleucine (1)                         64.60 (17.47)     66.14 (17.66)     .738                   .09
                Isoleucine (2)                         218.13 (92.84)    218.34 (129.83)   .994                   .002
                Leucine (1)                            128.23 (27.82)    126.76 (30.26)    .846                   .05
                Leucine (2)                            344.37 (134.99)   342.90 (137.30)   .967                   .01
                Tyrosine (1)                           67.27 (12.50)     66.45 (18.53)     .843                   .05
                Tyrosine (2)                           170.40 (41.242)   196.55 (82.14)    .132                   .40
                Phenylalanine (1)                      59.33 (8.53)      58.93 (9.54)      .865                   .04
                Phenylalanine (2)                      111.07 (43.94)    120.07 (63.98)    .530                   .16
                Tryptophan (1)                         61.97 (9.63)      59.21 (9.80)      .280                   .28
                Tryptophan (2)                         201.53 (77.05)    7.83 (5.33)       **2.68 × 10** ^--14^   3.55

Note: (1) signifies baseline values; (2) denotes results from sample taken after approximately 4.5 h. TRP:LNAA is the ratio between tryptophan and all large neutral amino acids (listed in table), thought to be most reflective of brain serotonin ([@bibr5-0269881120907991]). Emboldened values indicate statistical significance at *p* \< .05.

Results {#section3-0269881120907991}
=======

There were no differences between groups in age, years of education, depressive symptoms, or trait anxiety (*p*s \> .05). We achieved a robust depletion of tryptophan (*t*~(49)~ = −17.726, *p* = 4.857 × 10^--23^; degrees of freedom (df) were adjusted after Levene's test showed unequal variances; we were unable to obtain blood samples from three participants), without affecting mood (*t*~(55)~ = −1.341, *p* = .186; data unavailable for five participants). ATD did not affect the core measures of choice behaviour in PRL ([Table 1](#table1-0269881120907991){ref-type="table"}). After placebo, 31/32 participants attained criterion performance in acquisition; after ATD, 30/30 (Fisher's exact test, *p* = 1). On placebo, 29/32 participants reached reversal criterion, 28/30 on ATD (*p* = 1). Analysis of variance with condition (placebo, ATD) and sex (male, female) as the between-subjects factors, and phase (acquisition, reversal) as the within-subjects factor revealed no effects of condition or sex on the number of correct responses (*F* \< 1.60, *p* \> .05, and η~p~^2^ \< .03 for all terms involving ATD and sex); trials to criterion (*F* \< 3.10, *p* \> .05, and η~p~^2^ \< .055); SNF (*F* \< 3.00, *p* \> .05, and η~p~^2^ \< .050), shown in [Figure 1](#fig1-0269881120907991){ref-type="fig"}; or win--stay to veracious feedback (*F* \< 3.10, *p* \> .05, and η~p~^2^ \< .055). Perseveration was unaffected both immediately following reversal (*t*~(60)~ = .536, *p* = .594, *d* = .137) and across the reversal phase (*t*~(60)~ = −.170, *p* = .865, *d* = .042), and neither measure differed between males and females (*t*~(60)~ = 1.535, *p* = .130,*d* = .39; t~(60)~ = .263, *p* = .793, *d* = .07, respectively). There were no correlations between the extent of depletion and our key measures of interest: SNF, win--stay to veracious feedback, and either measure of perseveration (*p*s \> .05).

![Probabilistic reversal learning task: mean proportion of lose--shift behaviour (probability of shifting) following spurious negative feedback, plotted separately for acquisition and reversal, compared between placebo and ATD groups. Error bars: +/-- 1 standard error.](10.1177_0269881120907991-fig1){#fig1-0269881120907991}

Conclusion {#section4-0269881120907991}
==========

ATD did not affect the core measures of PRL choice behaviour. By nearly tripling the sample size and testing both sexes we considerably extended previous efforts to capture the effects of ATD, and replicated null results on choice ([@bibr4-0269881120907991]; [@bibr6-0269881120907991]). We tested additional measures, beyond those reported in the previous ATD PRL studies, to no avail. This contrasts with other serotonergic challenges that have modulated PRL -- and SNF in particular -- in healthy humans ([@bibr2-0269881120907991]; [@bibr9-0269881120907991]), rats ([@bibr1-0269881120907991]) and monkeys ([@bibr8-0269881120907991]). The discrepancy is likely to be due to both differences in the magnitude of change -- ATD is mild in comparison to neurotoxic depletion via 5,7-dihydroxytryptamine -- and the regions preferentially affected. Increased SNF in depression, for instance, is mediated by amygdala hyperactivity ([@bibr10-0269881120907991]), yet [@bibr4-0269881120907991] reported no effect of ATD on the amygdala during PRL. However, [@bibr8-0269881120907991] demonstrated that serotonin in both the amygdala and orbitofrontal cortex is required for PRL. It is possible that computational methods, as used in [@bibr8-0269881120907991], could reveal an effect of ATD on the latent mechanisms of PRL. Future studies should additionally employ more salient feedback. The implication of the present results, in conjunction with previous studies, is that under certain task demands ATD does not necessarily produce effects that parallel acute SSRI or neurotoxic serotonin depletion.
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